

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Apex Kidney Care secures \$9 M investment from Blue Earth Capital AG

06 February 2025 | News

For enhancing accessible, high-quality kidney care in India



Mumbai-based Apex Kidney Care (AKC) has received \$9 million in Foreign Direct Investment (FDI) from investment vehicles of Blue Earth Capital AG (BlueEarth), a Switzerland-based global impact investment firm, for an undisclosed equity stake.

This investment was facilitated by Tata Capital Healthcare Fund (TCHF), the healthcare-focused private equity fund of Tata Capital Ltd., reinforcing their collective commitment to enhancing accessible, high-quality kidney care in India. Last year, TCHF invested an equivalent amount in AKC, through a similar equity investment.

Speaking on the partnership, Visalakshi Chandramouli, Managing Partner at Tata Capital Healthcare Fund II said "This collaboration highlights our shared commitment to meeting the growing need for accessible, high-quality dialysis care in India. Co-investments remain a vital part of TCHF's strategy, providing portfolio companies with enhanced access to growth capital and opportunities."

"We are delighted to welcome BlueEarth as our Investor Partner. Together with TCHF and BlueEarth, we will continue our mission to expand and strengthen our comprehensive ecosystem for kidney disease patients. BlueEarth's and TCHF's confidence in our business ethics and philosophy is a great source of motivation for our team. We remain committed to driving growth by enhancing accessibility, with a strong focus on automation and quality. We will achieve this by collaborating with like-minded clinicians and hospitals, as well as partnering with government through PPP programs," said Dr Shrirang Bichu, co-founder of AKC.

Rohan Ghose, Director of Private Equity Partnerships at BlueEarth, commented, "By focusing on semi-urban and rural areas in India, AKC addresses a critical gap in healthcare delivery. What sets AKC apart is its commitment to clinical excellence and patient safety. Through this investment, we are partnering with mission-driven organisation, while creating meaningful social impact by improving access to life-saving dialysis treatment for underserved populations."